ScinoPharm Taiwan Ltd (台灣神隆) yesterday said it expects sales to grow steadily this year, but added that it plans to diversify its business from generic active pharmaceutical ingredients (API) to contract manufacturing and research services in a bid to avoid an intense price competition in the generic API market.
The Tainan-based pharmaceutical company reported revenue of NT$3.52 billion (US$114.3 million) for last year, inching up 0.2 percent from a year earlier.
However, thanks to cost controls, net profit rose 4.9 percent annually to NT$443 million, or earnings per share of NT$0.56, the company said.
Revenue from generic API accounted for 65 percent of total revenue, maintaining its top ranking, while combined revenue from contract manufacturing and research services made up 34 percent, company data showed.
ScinoPharm this year expects to gain regulatory approval in the US to supply generic APIs for a treatment for breast cancer and benign prostatic hyperplasia, as well as approvals in China and Japan for two other generic APIs, ScinoPharm marketing and sales vice president Portia Lin (林靜雯) told an investors’ conference in Taipei.
“However, we found that the prices of generic APIs fell significantly due to intense competition, and we could not win over our peers in countries with lower manufacturing costs, such as India and China,” Lin said.
ScinoPharm’s revenue from generic APIs last year fell 5.6 percent annually to NT$75.8 million, but revenue from contract manufacturing and research services jumped 10.4 percent and 64.7 percent annually to NT$17.2 million and NT$22.4 million respectively, company data showed.
Instead of seeking more API clients, the company plans to expand its contract manufacturing and research services this year, in the hope of boosting revenue contribution from the two segments to 40 percent of overall revenue.
This year, the company aims to focus more on the markets in Japan and China, which offer faster growth opportunities, compared with slowing growth in the US and Europe, where opportunities are further constrained by large-scale mergers and acquisitions in the pharmaceuticals sector, ScinoPharm said.
ScinoPharm shares yesterday rose 1.14 percent to NT$26.7 in Taipei. They have advanced 10.56 percent since the beginning of this year, compared with the broader market’s 9.41 percent rise over the same period.
Taiwanese firms have increased investment in the Philippines in recent years as Manila’s ties with Washington deepen and global supply chains continue to shift away from China, an expert at the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The Philippines had not been among Taiwanese investors’ top choices in Southeast Asia, CIER Taiwan ASEAN Studies Center director Kristy Hsu (徐遵慈) said at a seminar in Taipei. However, Taiwan’s investment in the country has grown significantly since the COVID-19 pandemic, reaching US $257 million last year, a high in recent years, she said. Although Taiwan’s total investment in the Philippines still lags
Intel Corp regards Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) as a longstanding partner, as the US chipmaker would continue outsourcing production of advanced chips to TSMC, Intel chief executive officer Lip-Bu Tan (陳立武) said yesterday. “I don’t look at people as competitors. I look at the collaboration... Nvidia is also, you know, a good friend,” Tan told a news conference following his keynote speech at the Computex trade show in Taipei. “It’s a very trusted partnership for us... We are a big, top customer for them, and we’re going to continue doing that,” he said, referring to TSMC, the world’s largest foundry
Hon Hai Precision Industry Co (鴻海精密) yesterday said it would work with US chipmaker Intel Corp to jointly develop and deploy next-generation artificial intelligence (AI) infrastructure and intelligent computing platforms in a move to capture booming demand for AI computing systems. Hon Hai, also known as Foxconn Technology Group (富士康), said in a statement that the partnership would combine its global manufacturing scale, system integration expertise and AI data center deployment capabilities with Intel’s strengths in processor architecture, silicon technologies and software ecosystem. The companies said they plan to work on equipment used in AI data centers, including server racks powered by
Artificial intelligence (AI) agents would supplant smartphones as the center of people’s digital lives, fundamentally reshaping personal devices and driving a major computing upgrade cycle, Qualcomm Inc CEO Cristiano Amon said yesterday. In his keynote speech for this year’s Computex trade show in Taipei, Amon said that the rise of "agentic AI" — AI systems capable of reasoning, planning and carrying out tasks autonomously — would transform how people interact with technology across phones, PCs, vehicles and wearable devices. Describing the technology as the next major evolution in computing, Amon said that "2026 is the year of agents.” For decades, smartphones have sat
RSS